NDT Advance Access originally published online on December 5, 2005
Nephrology Dialysis Transplantation 2006 21(3):677-682; doi:10.1093/ndt/gfi309
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Original Articles: Clinical Nephrology
Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals
1 Department of Internal Medicine, 2 Department of Clinical Chemistry, 3 Department of Nephrology, 4 Institute for Cardiovascular Research, VU University Medical Centre, Amsterdam, 5 Department of Internal Medicine, Amphia Hospital (Langendijk), Breda, 6 Department of Internal Medicine, Academic Hospital Maastricht and 7 Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
Correspondence and offprint requests to: Frank Stam, Department of Internal Medicine, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Email: f.stam{at}vumc.nl
Background. Patients with end-stage renal disease as well as mild renal impairment have an increased risk for the development of cardiovascular disease. It has been suggested that advanced glycation end-products (AGEs) are involved in atherogenesis, possibly through induction of endothelial dysfunction and low-grade inflammation.
Methods. In a cross-sectional, single-centre study, we investigated four groups of 20 non-diabetic subjects with a creatinine clearance ranging from normal (>90 ml/min/1.73 m2) to <31 ml/min/1.73 m2. We measured AGE-peptides, markers of endothelial dysfunction (von Willebrand factor, soluble E-selectin, plasminogen activator inhibitor-1, tissue-type plasminogen activator, soluble vascular cell adhesion molecule-1) and markers of inflammatory activity (soluble intercellular adhesion molecule-1, C-reactive protein, secretory phospholipase A2). We constructed composite endothelial dysfunction and inflammatory activity Z-scores using these markers.
Results. AGE-peptides were independently related to creatinine clearance (standardized ß –0.55, 95% confidence interval (CI) –0.77 to –0.34, P<0.001). AGE-peptides were not independently related to the individual markers of endothelial dysfunction and inflammation, nor to the composite endothelial dysfunction Z-score (standardized ß 0.08, 95% CI –0.14 to –0.30, P = 0.48) or the inflammatory activity Z-score (standardized ß –0.05, 95% CI –0.25 to –0.16, P = 0.66).
Conclusions. Plasma concentrations of AGE-peptides are associated with creatinine clearance but not with biochemical markers of endothelial dysfunction and inflammatory activity in non-diabetic patients over a wide range of renal function. This suggests that the atherogenic effects of AGE-peptides in individuals with renal functional impairment are not mediated by endothelial dysfunction or inflammatory activity as estimated by the markers used.
Keywords: advanced glycation end-products; cell adhesion molecules; chronic inflammation; creatinine clearance; endothelial dysfunction; von Willebrand factor